Sorry, you need to enable JavaScript to visit this website.

INVOKANA® (canagliflozin) Official Website HCP

FIRST

In adults with DKD* and T2D, INVOKANA®: the first SGLT2i indicated to reduce the risk of 6,7:

Pink icon with kidney graphic inside.

Pink heart icon with heartbeat graphic inside.

  • ESKD†
  • Doubling of serum creatinine
  • CV death
  • Hospitalization for heart failure

See data

ONLY

In adults with T2D and established CVD, INVOKANA®: the only SGLT2i indicated to reduce the risk of 5:

Purple heart icon with lightning bolt inside.

Purple brain icon.

Purple heart icon with heartbeat graphic inside.

  • All components of 3-point MACE:
    • Heart attack
    • Stroke
    • CV death

See data

*With albuminuria >300 mg/day.
†End-stage kidney disease was defined as dialysis for ≥30 days, kidney transplantation, or an eGFR <15 mL/min/1.73 m2 sustained for ≥30 days.
CV=cardiovascular; CVD=cardiovascular disease; DKD=diabetic kidney disease; ESKD=end-stage kidney disease; MACE=major adverse cardiovascular events; SGLT2i=sodium-glucose co-transporter 2 inhibitor; T2D=type 2 diabetes.